Senti Biosciences gets Nasdaq noncompliance notice; trading continues
Senti Biosciences Holdings received Nasdaq notices for failing the $1.00 minimum bid price and $2.5 million stockholders’ equity requirements for the Nasdaq Capital Market. Trading continues under SNTI, with until Feb 23, 2027 to regain bid-price compliance.
On August 27, 2026, the company received Nasdaq notices that it failed to meet the $1.00 minimum bid price and the $2.5 million stockholders' equity requirements for the Nasdaq Capital Market.
Trading continues under SNTI; the company has until Feb 23, 2027 to regain bid-price compliance and must s…